|
Affiliation |
Faculty of Medicine College Hospital Clinical oncology |
|
Title |
Professor |
|
External Link |
|
|
Related SDGs |
|
HOSOKAWA Ayumu
|
|
|
Papers 【 display / non-display 】
-
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. Reviewed
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H, Japan Oncology Network in Hepatobiliary and Pancreas
Journal of gastroenterology 60 ( 3 ) 356 - 367 2025.3
Language：English Publishing type：Research paper (scientific journal)
-
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302). Reviewed
Araki T, Hayashi K, Shimokawa M, Otsuka T, Sonoda Y, Honda T, Shibuki T, Nakazawa J, Arima S, Miwa K, Koga F, Ueda Y, Kubotsu Y, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Kawahira M, Arita S, Taguchi H, Tsuneyoshi K, Fujita T, Sakae T, Kawaguchi Y, Shirakawa T, Mizuta T, Mitsugi K
Therapeutic advances in medical oncology 17 17588359251320768 2025.2
Language：English Publishing type：Research paper (scientific journal)
-
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301). Reviewed
Araki T, Sonoda Y, Shimokawa M, Otsuka T, Hayashi K, Honda T, Nakao K, Shibuki T, Nakazawa J, Arima S, Miwa K, Okabe Y, Koga F, Ueda Y, Kubotsu Y, Shimokawa H, Takeshita S, Komori A, Nishikawa K, Otsu S, Hosokawa A, Oda H, Sakai T, Arita S, Kawahira M, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Shirakawa T, Mizuta T, Mitsugi K
Scientific reports 15 ( 1 ) 3427 2025.1
Language：English Publishing type：Research paper (scientific journal)
-
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial. Reviewed
Katada C, Yokoyama T, Watanabe A, Hara H, Yoshii T, Fujii H, Yamaguchi H, Nakajima TE, Izawa N, Ando T, Nomura M, Kojima T, Yamashita K, Kawakami S, Ishiyama H, Inoue Y, Sakamoto Y, Sasaki H, Ishikawa H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, Koizumi W
International journal of radiation oncology, biology, physics 120 ( 5 ) 1353 - 1362 2024.12
Language：English Publishing type：Research paper (scientific journal)
-
Naoki K., Igawa S., Uojima H., Tsumura H., Sengoku N., Karayama M., Shimomura A., Ohtake T., Shio Y., Hosokawa A., Komatsu Y., Kumagai Y.
Cancer 2024.11
Language：English Publishing type：Research paper (scientific journal) Publisher：Cancer
Background: Pimitespib (TAS-116), a first-in-class, oral, selective heat-shock protein 90 inhibitor, is approved as fourth-line treatment for gastrointestinal stromal tumors in Japan. This phase 1 study evaluated the cardiac safety of pimitespib. Methods: In this open-label, nonrandomized, multicenter study, Japanese patients (aged ≥20 years) with refractory, advanced solid tumors received placebo on day −1, then pimitespib 160 mg daily on days 1–5 of the cardiac safety evaluation period. Electrocardiograms were conducted at baseline, and on days −2, −1, 1, and 5; and blood samples were collected on days 1 and 5. Patients then received once-daily pimitespib for 5 days every 3 weeks. The primary end point was the time-matched difference in QT interval corrected for heart rate using the Fridericia correction (QTcF) between pimitespib and placebo. Pharmacokinetics, safety, and preliminary efficacy were also assessed. Results: Of the 22 patients in the cardiac safety-evaluable population, no clinically relevant QTc prolongation was observed; the upper bound of the one-sided 95% confidence interval for the time-matched difference in change from baseline in QTcF was <20 msec at all time points on days 1 and 5. Pimitespib pharmacokinetic parameters were consistent with previous data, and the time-matched difference in change from baseline in QTcF showed no marked increase as plasma concentrations increased. The safety profile was acceptable; 40% of patients experienced grade 3 or greater adverse drug reactions, mostly diarrhea (20%). The median progression-free survival was 3.1 months. Conclusions: In Japanese patients with refractory, advanced solid tumors, pimitespib was not associated with clinically relevant QTc prolongation, and there were no cardiovascular safety concerns. Plain Language Summary: Pimitespib is a new anticancer drug that is being used to treat cancer in the stomach or intestines (gastrointestinal stromal tumors). This study demonstrated that pimitespib had no marked effect on heart rhythm or negative effects on the heart or blood vessels and had promising anticancer effects in Japanese patients with advanced solid tumors who were unable to tolerate or benefit from standard treatment.
DOI： 10.1002/cncr.35447
Books 【 display / non-display 】
-
【逸脱症例から学ぶ がん薬物療法 標準治療の実践!】(第1章)がん薬物治療 再発大腸がん
米澤玲美, 細川 歩（ Role： Joint author , 第1章 がん薬物治療, 10. 再発大腸がん）
勝俣範之編, 48-50, 月刊薬事 61巻 第10号, 株式会社じほう 2019
Language：Japanese Book type：General book, introductory book for general audience
-
消化器がん化学療法 副作用マネジメント プロのコツ改訂第2版
柴田伸弘, 細川 歩（ Role： Joint author , 第III章 【副作用症状別】プロのコツ 3. 腎・泌尿器）
小松 嘉人(編). メジカルビュー社, 283-296 , 2019 2019
Language：Japanese Book type：General book, introductory book for general audience
-
特集I 大腸癌化学療法 大腸癌化学療法における血管新生阻害薬の位置づけ
中島孝治, 柴田伸弘、田原良博, 細川歩（ Role： Joint author）
消化器・肝臓内科, 5: 24-32, 2019 2019
Language：Japanese Book type：General book, introductory book for general audience
Presentations 【 display / non-display 】
-
消化器悪性腫瘍に対する薬物療法の進歩 当科における膵癌化学療法の現状 FOLFIRINOX療法とGEM/nab-PTX療法について
田原 良博, 細川 歩, 中島 孝治, 米澤 瑛美, 坂元 一樹, 山嶋 友実, 宮後 冴, 米澤 玲美, 黒木 大介, 野田 貴穂, 鈴木 翔, 久保田 良政, 松本 英丈, 芦塚 伸也, 安倍 弘生, 三池 忠, 坂 哲臣, 山本 章二朗, 稲津 東彦, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Symposium, workshop panel (public)
-
Pembrolizumabを投与したMSI-High大腸癌の1例
田村 穂高, 中島 孝治, 田原 良博, 細川 歩, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
Methotrexate+5-fluorouracil療法が著効したDIC合併胃癌骨髄癌腫症の1例
井手 雄太郎, 米澤 瑛美, 田原 良博, 貴島 翔子, 坂元 一樹, 野田 貴穂, 鈴木 翔, 安倍 弘生, 三池 忠, 山本 章二朗, 中島 孝治, 日高 智徳, 細川 歩, 下田 和哉, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
当院における切除不能進行・再発胃癌に対するニボルマブ療法の現状
米澤 玲美, 細川 歩, 中島 孝治, 田原 良博, 山嶋 友実, 宮後 冴, 松本 英丈, 芦塚 伸也, 稲津 東彦, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC
細川歩, 設樂 紘平, 西川和宏, 藤谷和正, 保坂尚志, 肥田圭介, 間狩洋一, 天貝賢二, 行澤 斉悟, 安藤 孝将, David H Ilson, Josep Tabernero, 土井 俊彦
第17回日本臨床腫瘍学会学術集会
Event date： 2019.7.18 - 2019.7.20
Language：English Presentation type：Oral presentation (general)
Past consigned research fund received 【 display / non-display 】
-
EFFECT OF TAS-116 ON CARDIOVASCULAR SAFETY PARAMETERS IN PATIENTS WITH ADVANCED SOLID TUMORS
2020.02 - 2020.12
Investigational New Drug Test
Consigned research type：Investigational New Drug Test